2019
Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.
Mahal A, Butler S, Franco I, Pike L, Zhao S, Sanford N, Dess R, Feng F, D'Amico A, Spratt D, Yu J, Nguyen P, Rebbeck T, Mahal B. Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Journal Of Clinical Oncology 2019, 37: 12-12. DOI: 10.1200/jco.2019.37.7_suppl.12.Peer-Reviewed Original ResearchLow-risk prostate cancerPositive biopsy coresProstate cancerShort-term outcomesBiopsy coresManagement of low-risk prostate cancerOlder patientsConservative managementMen ageActive surveillance/watchful waitingRate of conservative managementOlder menShort-term safetyDefinitive treatmentYounger patientsEnd ResultsOverall mortalityOptimal managementPatientsQuality of life implicationsNational databaseCancerMenAgeOutcomes
2018
Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
Johnson S, Yu J. Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Current Oncology Reports 2018, 20: 66. PMID: 29959582, DOI: 10.1007/s11912-018-0711-0.Peer-Reviewed Original ResearchConceptsBladder-preserving trimodality therapyTrimodality therapyRadical cystectomyBladder cancerMuscle-invasive urothelial carcinomaMuscle-invasive bladder cancerAlternative to cystectomySatisfactory quality of lifeBladder preservationOncological outcomesUrothelial carcinomaCystectomyFuture trialsBladderFunctional outcomesTherapyDisease outcomePatientsQuality of lifeTrimodalityCancerOutcomesCarcinoma
2017
Outcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance.
Mahal A, Mahal B, Nguyen P, Yu J. Outcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance. Journal Of Clinical Oncology 2017, 35: 198-198. DOI: 10.1200/jco.2017.35.6_suppl.198.Peer-Reviewed Original ResearchProstate cancer-specific mortalityHigh-risk prostate cancerProstate cancerTreatment of high-risk prostate cancerInsurance statusCompeting-risks regression modelsHigh-risk CaPPrivately insured menGray's competing-risks regression modelHigh-risk diseaseCancer-specific mortalityEnd Results ProgramMultivariate logistic regressionMetastatic diseaseNon-black menResults ProgramPrivate insuranceInsured menAfrican American menLogistic regressionMetSOutcomesCancerMenMore-than-additive effect